TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02569060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Testing and Monitoring of Blood Glucose Levels
Description: Point-of-care testing of HbA1c levels at the food pantry at approximately 3 month intervals

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Testing and Monitoring of Blood Glucose Levels
Description: Point-of-care testing of HbA1c levels at the food pantry at approximately 3 month intervals

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary care coordination
Description: Referral to a local primary care provider, if none currently exists. Coordination of care with primary care provider.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Primary care coordination
Description: Referral to a local primary care provider, if none currently exists. Coordination of care with primary care provider.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes-appropriate food packages
Description: Food (perishable and non-perishable) appropriate for diabetes self-management available for pick-up at the food pantry twice monthly.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes-appropriate food packages
Description: Food (perishable and non-perishable) appropriate for diabetes self-management available for pick-up at the food pantry twice monthly.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes self-management education
Description: Education materials drawn from evidence-based practice and adapted from existing diabetes education curricula to be flexible to individual, community, and site variations. The Immediate Intervention Arm receives more robust diabetes self-management education (with group education visits) than the Waitlist Control Arm.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes self-management education
Description: Education materials drawn from evidence-based practice and adapted from existing diabetes education curricula to be flexible to individual, community, and site variations. The Immediate Intervention Arm receives more robust diabetes self-management education (with group education visits) than the Waitlist Control Arm.
Study: NCT03903380

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy and Usual care exercise protocol for neck pain
Description: Manual Therapy protocol between four to eight sessions and exercise protocol will be progressively added to the intervention (from the fouth session of MT approximately).
Study: NCT00852514

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance-guide dry weight reduction
Description: for optimal determination of fluid status, monthly BIA was performed to monitor fluid status and avoid dehydration
Study: NCT02036151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: xylitol
Description: Mothers in the experimental group were instructed to chew 1 pellet of xylitol gum (Fennobon Oy, Yrittäjäntie, Finneland -gum, 3 times ) for a period of 3 months. control mothers did not receive any medications. All mothers received oral hygiene instructions and restorative treatment when needed. Offspring of both the experimental and control groups did not receive any medication and were followed for at 6,12, 18 and 24 month from initiation of mothers consumption. month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoride varnish application
Description: The control group participated in a preventive program under the supervision of the Pediatric Dentistry Department. The program activities consisted of oral hygiene instructions, fluoride varnish application (Duraphat 5% Na F ,Ultradent Products, Utah, USA) and restorative treatment when needed.
Study: NCT02825797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117
Description: Intravenous infusion of 3BNC117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117
Description: Intravenous infusion of 3BNC117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117
Description: Intravenous infusion of 3BNC117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117
Description: Intravenous infusion of 3BNC117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117
Description: Intravenous infusion of 3BNC117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-1074
Description: Intravenous infusion of 10-1074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-1074
Description: Intravenous infusion of 10-1074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-1074
Description: Intravenous infusion of 10-1074
Study: NCT03903380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy and Augmented reality exercise protocol
Description: Manual Therapy protocol between four to eight sessions and Augmented reality exercise protocol will be progressively added to the intervention (from the fouth session of MT approximately).
Study: NCT04835012

Intervention type: OTHER
Intervention: Medical debt forgiveness
Description: A non-profit charity, RIP Medical Debt, bought and retired medical debt for individuals that were assigned to the treatment group.
Study: NCT01120665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol valerate
Description: estradiol valerate, 1 mg/day, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol valerate
Description: estradiol valerate, 1 mg/day, orally.
Study: NCT02825797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-1074
Description: Intravenous infusion of 10-1074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-1074
Description: Intravenous infusion of 10-1074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analytical treatment interruption
Description: Analytical treatment interruption

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion of placebo (sterile saline)
Study: NCT01120665

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Aerobic trainin (cycleergometer, 3x/week, moderate intensity, 50 minutes)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Aerobic trainin (cycleergometer, 3x/week, moderate intensity, 50 minutes)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: lactose powder, corn starch, microcrystalline cellulose, and magnesium stearate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: lactose powder, corn starch, microcrystalline cellulose, and magnesium stearate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: The control group was advised to maintain their normal habits, and not to begin any physical exercise program during the study period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: The control group was advised to maintain their normal habits, and not to begin any physical exercise program during the study period
Study: NCT02894840

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: an inactivated influenza vaccine
Description: The vaccine will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
Study: NCT01652287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BB-12 supplemented strawberry yogurt
Description: Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12) probiotic supplemented yogurt, 4 ounces taken orally for 10 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Strawberry flavored yogurt
Description: Placebo, strawberry yogurt, 4 ounces taken orally for 10 days
Study: NCT02000804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darapladib 160mg
Description: drug
Study: NCT04360356

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ivermectin plus Nitazoxanide
Description: Ivermectin 200 mcg/kg once orally on empty stomach plus Nitazoxanide 500 mg twice daily orally with meal for 6 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Oxygen via Ventilators
Study: NCT02098954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine platinum combined with erlotinib
Description: patients will received a 28 days gemcitabine platinum combined with erlotinib scheme, after 4 cycles combined chemotherapy, patients will receive erlotinib for maintain treatment until progression disease.Gemcitabine for day 1 and day 8, 1250mg/m2. Platinum for day 1, 75mg/m2. Erlotinib for day 9-21 during combined chemotherapy, 150mg/day, then erlotinib should be used daily until patients develop progression disease.
Study: NCT02825797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion of placebo (sterile saline)
Study: NCT01523847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBVD (Myocet+BVD)
Description: MBVD will be scheduled as follows:~Myocet 25 mg/mq i.v. day 1 and 15 Bleomycin 10 mg/mq i.v. day 1 and 15 Vinblastine 6 mg/mq i.v. day 1 and 15 Dacarbazine 375 mg/mq i.v. day 1 and 15
Study: NCT06119750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NS Solution
Description: This will be administered via skin patch.
Study: NCT02473536

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiation therapy
Description: SABR
Study: NCT04382664

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UV1
Description: UV1 vaccine (300 μg) will be injected intradermally.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Sargramostim (75 μg) is used as a vaccine adjuvant.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Ipilimumab is dosed according to label.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is dosed according to label.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab is dosed according to label.
Study: NCT06119750

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: This will be administered via skin patch.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SLS
Description: This will be administered via skin patch.
Study: NCT04382664

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is dosed according to label.
Study: NCT01860183

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Mycophenolate will be administered to all study patients at dose of 3 g daily for the first seven days posttransplant. Afterwards, study patients will continue, as randomized, on either 3 g, or 2 g MMF daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Mycophenolate will be administered to all study patients at dose of 3 g daily for the first seven days posttransplant. Afterwards, study patients will continue, as randomized, on either 3 g, or 2 g MMF daily.
Study: NCT05853328

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epley Maneuver
Description: The patient is sitting with both feet on the table or bed with the head looking forward. Subsequently, they let themselves fall backwards with a pillow under the shoulder and the head is turned 45° to the right. They stay in this position for 30 seconds. Afterwards, they turn the head quickly 90° to the left side followed by a turn of the whole body to the left so that their nose is pointing at the floor. They stay in this position for another 30 seconds.~Subsequently, the patients sit themselves up with the head still turned 45° to the left. They can help themselves by using both arms. After a few seconds, they can turn the head slowly back to the neutral position facing forward.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SemontPLUS maneuver
Description: The patients first turn head 45° to the left. Then they extend the right arm and subsequently move the whole body by 150°+ to the right side. This position is kept for 60 seconds. Subsequently, patients move their whole body by 240° towards the non-affected side. Finally, after another 60 seconds, the patient sits up for another 60 sec.
Study: NCT02794220

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CN electronic cigarette 10 mg
Description: Inhalation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CN electronic cigarette 15 mg
Description: Inhalation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nicorette Inhalator 15 mg
Description: Inhalation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cigarette
Description: Inhalation
Study: NCT02463955

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: flexible video endoscope
Description: Thoracoscopy is done using flexible video endoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: video-rigid thoracoscope
Description: Thoracoscopy is done using video-rigid thoracoscope
Study: NCT00855660

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riociguat (Adempas, BAY63-2521) immediate release tablet of 2.5 mg
Description: Riociguat administered in a dose of 2.5 mg (single tablet), thrice daily, over 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered as a single tablet, thrice daily, over 14 days.
Study: NCT02641535

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise under hot and humid conditions protocol
Description: acclimatization day protocol: 2 hour effort performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (40 deg. centigrade \& 40% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously~experiment days (2 days): 2 hour effort (2 cycles of: 50 min walk and 10 min rest-sitting) performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (35 deg. centigrade \& 60% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BC membrane protective garment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NBC mask
Study: NCT02790866

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LuCaS Decision Aid
Description: Web-based Lung Cancer Screening Decision Aid
Study: NCT00966914

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel
Description: Paclitaxel 200 mg/m2 IV or Docetaxel 75mg/m2 IV every 3 weeks plus Cisplatin 80 mg/m2 IV every 3weeks plus Tavocept(BNP7787) 18.4gm/m2 IV every 3 weeks
Study: NCT02601313

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: brexucabtagene autoleucel
Description: A single infusion of brexucabtagene autoleucel (KTE-X19) anti-CD 19 CAR T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously
Study: NCT02790866

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NCI Website
Description: NCI Website on Lung Cancer Screening
Study: NCT02601313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: A single infusion of axicabtagene ciloleucel anti-CD 19 CAR T cells
Study: NCT00966914

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in combination with cisplatin and docetaxel or paclitaxel
Description: Paclitaxel 200 mg/m2 IV or Docetaxel 75mg/m2 IV every 3 weeks plus Cisplatin 80 mg/m2 IV every 3weeks plus Placebo IV every 3 weeks
Study: NCT04347603

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAVR
Description: Femoral percutaneous aortic prosthesis (TAVR)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAVR
Description: Femoral percutaneous aortic prosthesis (TAVR)
Study: NCT01796951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg daily
Description: In this single-arm trial, participants will take celecoxib 200 mg BID for 5 doses, followed by aspirin 325 mg daily for 10 days, followed by combination of celecoxib 200 mg BID for 5 doses and aspirin 325 mg daily for 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg BID
Description: In this single-arm trial, participants will take celecoxib 200 mg BID for 5 doses, followed by aspirin 325 mg daily for 10 days, followed by combination of celecoxib 200 mg BID for 5 doses and aspirin 325 mg daily for 3 days.
Study: NCT02675556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allo-hMSCs
Description: a single administration of allogeneic Human Mesenchymal Stem Cell (hMSCs): 100 x 10\^6 (100 million) allo-hMSCs of cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allo-hMSCs
Description: a single administration of allogeneic Human Mesenchymal Stem Cell (hMSCs): 100 x 10\^6 (100 million) allo-hMSCs of cells

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A
Study: NCT02678494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurofeedback training
Study: NCT03513653

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography with speckle-tracking imaging
Description: 1. Measurement of left ventricular ejection fraction and global longitudinal strain~2. Measurement of left atrial reservoir strain (peak atrial longitudinal strain)~3. Measurement of right ventricular global longitudinal strain
Study: NCT03057366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Pevonedistat intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Pevonedistat
Description: \[14C\]-Pevonedistat intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel intravenous infusion.
Study: NCT03562663

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: A constant, low current stimulation is provided non-invasively through sponge electrodes positioned over the motor cortex of the affected arm. The stimulation is provided for 20 minutes at an intensity of 2 mA.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Upper extremity robotics
Description: Participants complete robotic training 3 days per week for 12 weeks, or 36 sessions. The protocol alternates between planar (shoulder/elbow) and wrist robots for the duration of the study.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Upper extremity robotics
Description: Participants complete robotic training 3 days per week for 12 weeks, or 36 sessions. The protocol alternates between planar (shoulder/elbow) and wrist robots for the duration of the study.
Study: NCT01931761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [C14] selumetinib (oral)
Description: Single oral administration \[C14\] 75mg
Study: NCT03324204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Training
Description: Each session lasted 30 minutes and consisted of three sets of exercises with 20-30 repetitions. Emphasis was placed on proper knee alignment during exercise. Most of the women exhibited excessive medial rotation and adduction of the femur, resulting in knee valgus, although knee varus was also observed. The women were instructed how to correct their abnormalities using mirrors as visual feedback. All exercises were completed without pain. If the exercises were too easy, the level of difficulty was increased individually in accordance with the rehabilitation protocol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Description: ESWT will be applied to the iliotibial band and tensor fascia latae muscle with the following parameters: pressure - 4.5 bar, emission frequency -8 Hz, number of pulses per dose -2,500 per session
Study: NCT01294384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboxymethylcellulose sodium based New Eye Drop Formulation 1
Description: 1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation 1 in each eye at least twice daily for 90 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboxymethylcellulose sodium based New Eye Drop Formulation 2
Description: 1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation 2 in each eye at least twice daily for 90 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboxymethylcellulose sodium based Eye Drops
Description: 1 to 2 drops of carboxymethylcellulose sodium based Eye Drops (Refresh Tears®) in each eye at least twice daily for 90 days.
Study: NCT01324284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: Lubiprostone is a chloride channel activator approved by the Food and Drug Administration for the treatment of chronic constipation. A randomized, double-blind, parallel-group, placebo-controlled study evaluating the effect of lubiprostone on gastric function showed slowed gastric emptying and increased small bowel and colonic transit time. Peak plasma concentration was shown to be around 1.14 hours, with a majority of the drug excreted in the urine within 48 hours.
Study: NCT00652353

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 44-55-66-PM
Description: The mnemonic 44-55-66-PM helps to remember the components of the Ottawa Ankle and foot Rule.~44: Is to remember that an X-ray is required if the patients is unable to walk 4 steps at the moment of the Accident AND during the physical examination 55: Is to remember that an X-ray of the foot is required if the patient has pain at the basis of the 5Th metatarsal of at the 5caphoid 66-PM: Is to remember that an X-ray of the ankle is required if the patient has pain in the Posterior of the lateral or medial malleolar

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: Participants will be instructed of the components of the Ottawa Ankle Rule on a standardized sheet
Study: NCT02012556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesamorelin
Study: NCT02117726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine,midazolam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol,midazolam